Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other hematologic neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 184Mesothelioma, Malignant 183Mesothelioma 145Solid Tumor 135Retinoblastoma 96Solid Tumors 86Advanced Solid Tumor 60Advanced Solid Tumors 50Solid Tumor, Adult 47Hematopoietic and Lymphatic System Neoplasm 47Carcinoma, Non-Small-Cell Lung 42Lung Neoplasms 33Sarcoma 28Hematopoietic and Lymphoid System Neoplasm 23Small Cell Lung Carcinoma 21Pancreatic Neoplasms 20Stomach Neoplasms 19Neuroblastoma 19Melanoma 19Carcinoma, Renal Cell 19Ovarian Neoplasms 18Neoplasms 17Wilms Tumor 15Colorectal Neoplasms 15Breast Neoplasms 15Osteosarcoma 13Solitary Fibrous Tumor, Pleural 12Rhabdomyosarcoma 12Refractory Solid Tumors 12Esophageal Neoplasms 12

Interventions

Immune Checkpoint Inhibitors 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Immune-related Adverse Event × Other solid neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡